HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle Grows Skin Care Footprint, Valeant Gains Antitrust Cover In Derma Deal

This article was originally published in The Tan Sheet

Executive Summary

Swiss food and beverage firm Nestle grows its stake in North American skin care with its pending $1.4 billion acquisition from Valeant of five aesthetic dermatology brands, demonstrating its commitment to health and wellness, analysts say. Valeant resolves potential antitrust obstacles to its proposed Allergan acquisition.

You may also be interested in...



Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS139406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel